Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination

• Published in: Vaccine Vol. 36; no. 16; pp. 2057 - 2060
• Main Authors: Chen, C., Beutels, P., Newall, A.T.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 12-04-2018; Elsevier Limited
• Subjects: Adults; Age; Babies; Cost analysis; Disease; Evolution of serotype; Herd immunity; Immunization; Infants; Markov model; Older people; PCV13; Pharmaceuticals; Pneumonia; Serotypes; Streptococcus infections; Vaccination; Vaccines; England; United Kingdom > UK; Australia; New South Wales Australia; Herd immunity; PCV13; Pneumonia; Immunization; Markov model; Evolution of serotype
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2018.03.006

In many settings, serotype changes as a result of infant 13-valent pneumococcal conjugate vaccine (PCV13) programs are likely to continue after the introduction of adult PCV13 programs. We applied a multi-cohort model to explore how potential serotype changes may impact on the cost-effectiveness of PCV13 use in Australian adults aged over 65 years. We found assumptions around continued herd protection from infant PCV13 programs to be critical when assessing the cost-effectiveness of adult PCV13 vaccination in Australia. Future cost-effectiveness analyses of adult PCV13 programs need to carefully consider how to predict these future changes in serotypes, with Australian data suggesting that the changes post-PCV13 use in infants may be different than post-PCV7.